J Cancer 2019; 10(20):4793-4806. doi:10.7150/jca.32475

Review

Glioblastoma Treatment Modalities besides Surgery

Hao Zhang1*, Ruizhe Wang2*, Yuanqiang Yu1, Jinfang Liu1, Tianmeng Luo3, Fan Fan1,4✉

1. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
2. Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
3. Department of Medical Affairs, Xiangya Hospital, Central South University, Chang Sha, Hunan Province, China
4. Center for Medical Genetics & Hunan Provincial Key Laboratory of Medical Genetics, School of Life Sciences, Central South University Changsha, China
*Equal contribution

Abstract

Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy from surgery, chemotherapy, to radiotherapy. Efforts in recent decades have brought many novel therapies to light, however, with limitations. In this paper, authors reviewed current treatments for GBM besides surgery. In the past decades, only radiotherapy, temozolomide (TMZ), and tumor treating field (TTF) were approved by FDA. Though promising in preclinical experiments, therapeutic effects of other novel treatments including BNCT, anti-angiogenic therapy, immunotherapy, epigenetic therapy, oncolytic virus therapy, and gene therapy are still either uncertain or discouraging in clinical results. In this review, we went through current clinical trials, underlying causes, and future therapy designs to present neurosurgeons and researchers a sketch of this field.

Keywords: glioblastoma, novel treatment, therapy

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F. Glioblastoma Treatment Modalities besides Surgery. J Cancer 2019; 10(20):4793-4806. doi:10.7150/jca.32475. Available from http://www.jcancer.org/v10p4793.htm